Paris Panayiotopoulos

Paris Panayiotopoulos is a member of the Board of Directors of Anthos Therapeutics.

Mr. Panayiotopoulos is a Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Mr. Panayiotopoulos is focused on growth investments in the biopharmaceutical space.

In over twenty years in the biopharmaceutical industry, Mr. Panayiotopoulos has served on the Board of Directors of a number of start-up to commercialization stage companies, as CEO and a member of the Board of Directors of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA, sold to Takeda Pharmaceuticals in 2017), and as President of the US, Japan and Serono R&D Institute biopharmaceutical businesses of Merck KgaA (FWB: MRK).